Study of Body Composition in Patients Treated by Adjuvant Hormonal Therapy for Breast Cancer (MetaCa2)
NCT ID: NCT02509871
Last Updated: 2018-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
33 participants
INTERVENTIONAL
2015-07-31
2016-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Body composition measurement
DXA, impedance
Body composition measurement
DXA, impedance
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Body composition measurement
DXA, impedance
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients requiring hormonal treatment
* WHO performance status 0-2
* patients initially included in MetaCa (AU882) protocol
* Affiliation to a social security scheme (or be the beneficiary of such a plan)
* patients who signed the informed consent form
Exclusion Criteria
* concurrent treatment with a drug test, or participation in a clinical trial within \< 30 days
* patients carrying an electronic medical device (eg pacemaker)
* patients who refused to sign the consent form
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Jean Perrin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xavier DURANDO, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Centre Jean Perrin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Jean Perrin
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ginzac A, Thivat E, Mouret-Reynier MA, Dubray-Longeras P, Van Praagh I, Passildas J, Abrial C, Kwiatkowski F, Boirie Y, Duclos M, Morio B, Gadea E, Durando X. Weight Evolution During Endocrine Therapy for Breast Cancer in Postmenopausal Patients: Effect of Initial Fat Mass Percentage and Previous Adjuvant Treatments. Clin Breast Cancer. 2018 Oct;18(5):e1093-e1102. doi: 10.1016/j.clbc.2018.06.010. Epub 2018 Jun 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-A00633-46
Identifier Type: -
Identifier Source: org_study_id